The Combination of Radiotherapy,Surufatinib and Sintilimab in High-Risk Localized Soft Tissue Sarcoma

This is a prospective, single-center, single-arm, phase Ib/II clinical trial. The study aims to evaluate the safety and efficacy of the treatment which combines radiotherapy, Sintilimab (Anti-PD1 Antibody) and Surufatinib (small-molecule Tyrosine Kinase inhibitor) in patients with high-risk localized soft tissue sarcoma. There will be 52 patients with high-risk localized extremity and trunck soft tissue sarcoma recruited. The trail is designed as a two-stage study. In safety lead-in phase (phase Ib), using 3+3 design, 6 cycles of Surufatinib (250mg, 200mg, qd) and Sintilimab (200mg, q3w) will

Trial Details

NCT ID
NCT05839275
Phase
PHASE1 / PHASE2
Sponsor
Fudan University
Status
RECRUITING
Cancer Type
Sarcoma
Interventions
  • Surufatinib
  • Sintilimab
  • Radiotherapy
Locations (sample)
  • Shanghai, Shanghai Municipality, China|31.22222,121.45806

Key Eligibility Criteria

  • Aged from 18 to 70, with life expectancy more than 2 years
  • Histologically confirmed STS, G2 or G3
  • Has imaging-confirmed localized lesions on the limbs or trunk without distant metastases
  • Has\>5 cm lesions, or the lesions are determined to be borderline resectable or unresectable by a multidisciplinary consultation.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Sarcoma Trials on Trialify →